Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
- Study expected to enrol first participants during Q3 CY2024
- 預計在2024年第三季度招募首批參與者。
SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761.
2024年7月17日，澳洲悉尼（GLOBE NEWSWIRE）--臨床階段的生物技術公司Immutep Limited((ASX: IMm, NASDAQ:IMMP)（“Immutep”或“公司”）宣佈已獲得荷蘭倫理和主管當局的監管批准，啓動IMP761人體第一期臨床研究。Immutep開發了針對癌症和自身免疫性疾病的新型LAG-3免疫療法。
IMP761 is the world's first therapeutic LAG-3 agonist antibody and as such is uniquely positioned in the treatment landscape for autoimmune diseases. The immune checkpoint LAG-3 has been identified as a promising target for agonist immunotherapy to treat rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among other autoimmune diseases.1,2,3 IMP761 is designed to restore balance to the immune system by enhancing the "brake" function of LAG-3 to silence unregulated self-antigen-specific memory T cells. These T cells accumulate at disease sites and are the underlying cause of many autoimmune diseases.
IMP761是世界上第一個治療性LAG-3激動劑抗體，因此在自身免疫性疾病的治療領域中處於獨特的位置。LAG-3免疫檢查點已被確定爲治療類風溼性關節炎、1型糖尿病和多發性硬化等自身免疫性疾病的有前途的靶點。 IMP761的設計是通過增強LAG-3的“剎車”功能來恢復免疫系統的平衡，以沉默未受調節的自身抗原特異性記憶T細胞。這些T細胞在疾病部位積累，並是許多自身免疫性疾病的潛在原因。
